Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy (vol 100, 688, 2023)

In the Disputes & Debates: Editors' Choice article Reader Response: Long-term Neurologic Safety in Patients With B-Cell Lymphoma Treated With Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy by Karschnia et al.,(1) the second author's name should be spelled Kai Rejeski. The article has been replaced by a corrected version. The editorial office regrets the error.

Automated summary

This article discusses the long-term neurologic safety in patients with B-cell lymphoma treated with anti-CD19 chimeric antigen receptor T-cell therapy. It points out an error in the spelling of the second author's name, which has been corrected.